Genomic Alterations in Metastatic Renal Cell Carcinoma
Patients with metastatic renal carcinoma (mRCC) treated with post-frontline agents had increased genomic alterations.
Genitourinary Cancers Symposium 2017
Adjuvant BEP for 1 Cycle Safe, Efficacious for Testicular Cancer
Bleomycin, etoposide, and cisplatin (BEP) for 1 cycle after orchiectomy is associated with a similar 2-year recurrence rate as BEP.
Urothelial Carcinoma: Year in Review
Studies presented in the last year demonstrated a revolutionary role for immune checkpoint inhibitors.
Pembrolizumab Improves Survival and Quality of Life in Advanced Bladder Cancer
Pembrolizumab following platinum-based chemotherapy was associated with significantly longer overall survival, fewer adverse events.
Bladder Cancer: Genomics May Predict Benefit from Neoadjuvant Chemotherapy
David J. McConkey, MD, PhD, described how genomics can affect the clinical management of patients with bladder cancer.
Bladder Cancer: Neoadjuvant Chemotherapy and Molecular Subtype
The clinical outcomes when using neoadjuvant chemotherapy for muscle-invasive bladder cancer vary by molecular subtype.
Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer
Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.
mCRPC: Full-length AR Copy Number Prognostic for Outcomes
Full-length androgen receptor (AR-FL) copy number derived from circulating tumor cells detected using a liquid biopsy.
2017 ASCO GU Symposium: Updates in Managing Small Renal Masses
At a general session at the 2017 ASCO GU Symposium, the latest advances in managing SRMs will be discussed.
Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Are Feasible
A phase 3 study presented at the 2017 Genitourinary Cancers Symposium demonstrated the feasibility of conducting adjuvant trials.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Genitourinary Cancers Symposium 2017
Loading... 
Loading...